Balloon Angioplasty Devices Market - Strategic Insights and Forecasts (2026-2031)'

Description

The Global Balloon Angioplasty Devices Market is forecast to grow at a CAGR of 4.9%, reaching USD 3.8 billion in 2031 from USD 3.0 billion in 2026.

Balloon angioplasty devices play a vital role in interventional cardiology and vascular procedures by restoring blood flow through narrowed or blocked arteries. These devices utilize inflatable balloon catheters that are positioned within affected blood vessels and expanded to compress plaque deposits against artery walls, thereby improving vascular patency. Balloon angioplasty remains one of the most widely performed minimally invasive procedures for the treatment of coronary artery disease, peripheral artery disease, and various vascular obstructions.

The increasing global burden of cardiovascular diseases continues to be the primary factor supporting market growth. Cardiovascular disorders remain among the leading causes of mortality and morbidity worldwide, creating substantial demand for effective treatment solutions. Factors such as aging populations, sedentary lifestyles, obesity, diabetes, hypertension, and tobacco consumption continue to contribute to rising cardiovascular disease prevalence, increasing the need for vascular intervention procedures.

The growing preference for minimally invasive treatments is significantly influencing market expansion. Compared with traditional open surgical procedures, balloon angioplasty offers several advantages, including reduced hospital stays, faster recovery times, lower complication rates, and improved patient outcomes. These benefits have encouraged healthcare providers and patients to increasingly adopt catheter-based interventions.

Technological advancements have transformed balloon angioplasty devices over the past decade. Manufacturers continue to develop specialized balloon technologies designed to improve procedural success and clinical outcomes. Innovations such as drug-coated balloons, cutting balloons, scoring balloons, high-pressure balloons, and specialty peripheral angioplasty devices are expanding treatment options for complex vascular conditions.

The increasing adoption of early diagnosis and preventive cardiovascular care is also contributing to market development. Improved screening programs and diagnostic imaging technologies are enabling earlier identification of vascular diseases, leading to increased intervention volumes and greater utilization of angioplasty devices.

Healthcare systems worldwide are investing heavily in cardiac care infrastructure, catheterization laboratories, and specialized cardiovascular treatment centers. These investments are improving access to advanced interventional procedures and supporting broader market penetration.

North America represents a major market due to the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, favorable reimbursement systems, and widespread adoption of innovative interventional technologies. Europe maintains a significant market position supported by established cardiovascular treatment programs and increasing demand for minimally invasive procedures. Asia Pacific is expected to experience the fastest growth due to rising cardiovascular disease incidence, expanding healthcare infrastructure, growing healthcare expenditure, and improving access to advanced medical technologies.

Market Drivers

The increasing prevalence of coronary artery disease and peripheral artery disease remains the most significant driver of the balloon angioplasty devices market. Growing numbers of patients requiring vascular interventions are supporting sustained demand for angioplasty procedures.

The rising global burden of cardiovascular risk factors, including diabetes, obesity, hypertension, smoking, and hyperlipidemia, is contributing to increased incidence of vascular diseases and subsequent treatment demand.

Growing adoption of minimally invasive cardiovascular procedures is accelerating market growth. Healthcare providers increasingly favor catheter-based interventions due to their clinical benefits and reduced patient recovery times.

Technological advancements in balloon catheter design continue to improve procedural efficiency and treatment outcomes. Drug-coated balloons, specialty balloons, and enhanced delivery systems are expanding the range of treatable vascular conditions.

Increasing investments in cardiovascular healthcare infrastructure are supporting greater access to interventional procedures. The expansion of catheterization laboratories and cardiac care facilities is creating favorable market conditions.

Growing awareness regarding cardiovascular health and preventive care is encouraging earlier diagnosis and treatment of vascular diseases, contributing to procedural volume growth.

The increasing elderly population is also supporting market expansion, as older individuals are more susceptible to cardiovascular and peripheral vascular diseases requiring angioplasty interventions.

Market Restraints

Despite favorable growth prospects, the market faces several challenges. One of the primary restraints is the risk of restenosis, where treated arteries may narrow again following angioplasty procedures, potentially requiring additional interventions.

The high cost of advanced angioplasty devices and cardiovascular procedures may limit accessibility in certain healthcare systems, particularly in developing regions.

Competition from alternative treatment options, including drug therapies, vascular surgery, atherectomy devices, and stent-based interventions, may influence market dynamics.

Procedure-related complications such as vessel injury, thrombosis, bleeding, and embolization can impact treatment decisions and patient outcomes.

Stringent regulatory requirements for cardiovascular medical devices may increase development timelines and commercialization costs for manufacturers.

Limited access to specialized cardiovascular care facilities and trained interventional specialists in certain regions may restrict procedural volumes and market expansion.

Economic pressures and healthcare budget constraints may affect purchasing decisions and technology adoption rates in some healthcare institutions.

Technology and Segment Insights

The market can be segmented by product type into standard balloon catheters, drug-coated balloons, cutting balloons, scoring balloons, high-pressure balloons, and specialty angioplasty balloons. Drug-coated balloons are gaining significant attention due to their ability to reduce restenosis rates and improve long-term outcomes.

By application, the market includes coronary angioplasty, peripheral angioplasty, carotid artery interventions, renal artery procedures, and other vascular treatments. Coronary angioplasty remains the largest application segment due to the widespread prevalence of coronary artery disease.

Based on end user, the market comprises hospitals, specialty cardiac centers, ambulatory surgical centers, and catheterization laboratories. Hospitals account for a major share of market demand due to the availability of advanced cardiovascular treatment infrastructure.

By indication, the market serves patients with coronary artery disease, peripheral artery disease, chronic total occlusions, in-stent restenosis, and other vascular conditions requiring revascularization procedures.

Technological developments such as improved balloon materials, enhanced catheter flexibility, advanced coating technologies, and precision delivery systems are contributing to better procedural outcomes and expanding treatment capabilities.

The integration of advanced imaging technologies, including intravascular ultrasound and optical coherence tomography, is further improving procedural planning and intervention accuracy.

Competitive and Strategic Outlook

The competitive landscape of the balloon angioplasty devices market is characterized by continuous innovation, product development, and strategic expansion activities. Manufacturers are focused on improving device performance, procedural efficiency, and long-term patient outcomes.

Companies are investing heavily in next-generation balloon technologies, particularly drug-coated and specialty balloons designed to address complex vascular lesions and reduce recurrence rates. These innovations are expected to strengthen competitive differentiation and drive market growth.

Strategic collaborations between medical device companies, healthcare providers, research institutions, and cardiovascular specialists are supporting product development, clinical validation, and commercialization efforts.

The growing focus on peripheral vascular interventions is creating new growth opportunities for market participants. Increasing recognition of peripheral artery disease and advancements in treatment technologies are expanding procedural volumes beyond traditional coronary applications.

Emerging markets present substantial opportunities due to improving healthcare infrastructure, increasing cardiovascular disease awareness, expanding insurance coverage, and rising healthcare expenditure.

Manufacturers are also focusing on physician training programs, clinical education initiatives, and post-market support services to strengthen customer relationships and improve adoption rates.

Future competition is expected to center on device performance, clinical outcomes, procedural simplicity, safety profiles, cost-effectiveness, and innovation in specialty balloon technologies. Companies capable of delivering advanced solutions across multiple vascular applications are likely to strengthen their market positions.

Conclusion

The balloon angioplasty devices market is positioned for sustained growth as cardiovascular diseases continue to represent a major global healthcare challenge. Rising prevalence of coronary and peripheral artery diseases, increasing adoption of minimally invasive procedures, technological advancements in balloon catheter systems, and expanding healthcare infrastructure are supporting long-term market development.

Although challenges related to restenosis, procedural costs, regulatory requirements, and competition from alternative therapies remain, ongoing innovation in drug-coated balloons, specialty angioplasty devices, and imaging-guided interventions is expected to strengthen market expansion. As healthcare systems continue to prioritize effective cardiovascular disease management and minimally invasive treatment approaches, balloon angioplasty devices will remain essential components of modern vascular care.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals. * Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches. * Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market. * Actionable Recommendations: Support strategic decisions to unlock new revenue streams. * Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031 * Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis * Competitive positioning, strategies, and market share evaluation, and trade analysis * Revenue growth and forecast assessment across segments and regions * Company profiling including strategies, products, financials, and key developments.

Product Code: KSI-008734

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
- 1.2.1 Growth Outlook
- 1.2.2 Technological Advancements
- 1.2.3 Adoption Trends in Coronary and Peripheral Interventions
- 1.2.4 Emerging Markets Opportunity Assessment
1.3 Strategic Imperatives
- 1.3.1 Product Innovation
- 1.3.2 Regulatory Compliance
- 1.3.3 Pricing and Reimbursement Optimization
- 1.3.4 Expansion in Ambulatory and Outpatient Settings
1.4 Analyst Recommendations

2. Disease & Epidemiology Analysis

2.1 Overview of Cardiovascular Diseases
- 2.1.1 Coronary Artery Disease (CAD)
- 2.1.2 Peripheral Artery Disease (PAD)
- 2.1.3 Chronic Total Occlusion (CTO)
- 2.1.4 In-Stent Restenosis (ISR)
- 2.1.5 Small Vessel Disease
2.2 Global Epidemiology of Cardiovascular Disorders
- 2.2.1 Prevalence of Coronary Artery Disease
- 2.2.2 Prevalence of Peripheral Artery Disease
- 2.2.3 Incidence of Percutaneous Coronary Intervention (PCI) Procedures
- 2.2.4 Aging Population and Cardiovascular Burden
- 2.2.5 Diabetes and Hypertension Impact on Angioplasty Demand
2.3 Procedure Volume Analysis
- 2.3.1 Coronary Angioplasty Procedures
- 2.3.2 Peripheral Angioplasty Procedures
- 2.3.3 Drug-Coated Balloon Procedures
- 2.3.4 Specialty Balloon Utilization Trends
2.4 Risk Factor Assessment
- 2.4.1 Obesity
- 2.4.2 Smoking
- 2.4.3 Sedentary Lifestyle
- 2.4.4 Dyslipidemia
- 2.4.5 Chronic Kidney Disease
2.5 Unmet Clinical Needs
- 2.5.1 Restenosis Prevention
- 2.5.2 Improved Deliverability and Flexibility
- 2.5.3 Long Lesion Treatment Challenges
- 2.5.4 Calcified Lesion Management
- 2.5.5 Treatment in Small Vessels and Bifurcation Lesions

3. Market Dynamics

3.1 Market Drivers
- 3.1.1 Rising Burden of Cardiovascular Diseases
- 3.1.2 Increasing PCI Volumes Globally
- 3.1.3 Growth in Minimally Invasive Procedures
- 3.1.4 Technological Advancements in Balloon Catheters
- 3.1.5 Increasing Adoption of Drug-Coated Balloons
3.2 Market Restraints
- 3.2.1 Product Recalls and Safety Concerns
- 3.2.2 High Cost of Advanced Balloon Technologies
- 3.2.3 Stringent Regulatory Requirements
- 3.2.4 Reimbursement Variability
3.3 Market Opportunities
- 3.3.1 Emerging Market Penetration
- 3.3.2 Expansion of Peripheral Interventions
- 3.3.3 Development of Scoring and Cutting Balloons
- 3.3.4 AI and Imaging Integration in PCI Planning
3.4 Market Challenges
- 3.4.1 Competitive Pricing Pressure
- 3.4.2 Physician Preference for Drug-Eluting Stents
- 3.4.3 Complex Lesion Treatment Limitations
- 3.4.4 Supply Chain and Raw Material Constraints
3.5 Porter's Five Forces Analysis
- 3.5.1 Bargaining Power of Suppliers
- 3.5.2 Bargaining Power of Buyers
- 3.5.3 Threat of New Entrants
- 3.5.4 Threat of Substitutes
- 3.5.5 Competitive Rivalry
3.6 PESTLE Analysis
3.7 SWOT Analysis

4. Commercial & Market Access

4.1 Pricing Analysis
- 4.1.1 Standard Balloon Catheters
- 4.1.2 Drug-Coated Balloons
- 4.1.3 Specialty Balloons
4.2 Reimbursement Landscape
- 4.2.1 Hospital Reimbursement Framework
- 4.2.2 Outpatient Reimbursement Trends
- 4.2.3 DRG and Bundled Payment Models
4.3 Procurement and Purchasing Trends
- 4.3.1 Group Purchasing Organizations (GPOs)
- 4.3.2 Hospital Tender Dynamics
- 4.3.3 Public vs Private Healthcare Procurement
4.4 Market Access Challenges
- 4.4.1 Cost-Effectiveness Assessment
- 4.4.2 HTA Considerations
- 4.4.3 Regulatory Approval Delays

5. Innovation & Pipeline Landscape

5.1 Technology Evolution
- 5.1.1 Semi-Compliant Balloon Technology
- 5.1.2 Non-Compliant Balloon Technology
- 5.1.3 Drug-Coated Balloon Technology
- 5.1.4 Scoring Balloon Technology
- 5.1.5 Cutting Balloon Technology
5.2 Pipeline Analysis by Development Stage
- 5.2.1 Commercially Approved Products
- 5.2.2 Late-Stage Pipeline Products
- 5.2.3 Early-Stage Development Technologies
5.3 Pipeline Analysis by Modality
- 5.3.1 Paclitaxel-Coated Balloons
- 5.3.2 Sirolimus-Coated Balloons
- 5.3.3 Specialty Balloons for Calcified Lesions
- 5.3.4 Bioresorbable Balloon Technologies
5.4 Clinical Trial Landscape
- 5.4.1 Coronary Balloon Angioplasty Trials
- 5.4.2 Peripheral Balloon Angioplasty Trials
- 5.4.3 Drug-Coated Balloon Clinical Evidence
- 5.4.4 Comparative Effectiveness Studies
5.5 Patent Analysis
5.6 Innovation Benchmarking

6. Treatment Landscape

6.1 Overview of Percutaneous Coronary Intervention (PCI)
6.2 Treatment Algorithms
- 6.2.1 Coronary Artery Disease
- 6.2.2 Peripheral Artery Disease
- 6.2.3 In-Stent Restenosis Management
- 6.2.4 Chronic Total Occlusion Management
6.3 Balloon Angioplasty Devices by Clinical Utility
- 6.3.1 Pre-Dilatation Balloons
- 6.3.2 Post-Dilatation Balloons
- 6.3.3 Drug-Coated Balloons
- 6.3.4 Specialty Balloons
6.4 Comparative Analysis of Interventional Devices
- 6.4.1 Balloon Angioplasty vs Drug-Eluting Stents
- 6.4.2 Balloon Angioplasty vs Atherectomy
- 6.4.3 Balloon Angioplasty vs Bypass Surgery
6.5 Guidelines and Recommendations
- 6.5.1 American College of Cardiology (ACC)
- 6.5.2 European Society of Cardiology (ESC)
- 6.5.3 Society for Cardiovascular Angiography and Interventions (SCAI)

7. Global Balloon Angioplasty Devices Market Size & Forecast

7.1 Global Market Overview
7.2 Market Revenue Forecast
- 7.2.1 Historical Market Size
- 7.2.2 Base Year Analysis
- 7.2.3 Forecast Period Analysis
7.3 Market Forecast by Product Type
7.4 Market Forecast by Application
7.5 Market Forecast by End User
7.6 Market Forecast by Region
7.7 Market Forecast by Country

8. Global Balloon Angioplasty Devices Market Segmentation

8.1 By Product Type
- 8.1.1 Standard Balloon Catheters
- 8.1.2 Drug-Coated Balloons
- 8.1.3 Cutting Balloons
- 8.1.4 Scoring Balloons
- 8.1.5 Others
8.2 By Material
- 8.2.1 Nylon Balloons
- 8.2.2 Polyurethane Balloons
8.3 By Application
- 8.3.1 Coronary Angioplasty
- 8.3.2 Peripheral Angioplasty
8.4 By End User
- 8.4.1 Hospitals
- 8.4.2 Cardiac Catheterization Laboratories
- 8.4.3 Ambulatory Surgical Centers

9. Geographical Analysis

9.1 North America
- 9.1.1 Market Size & Forecast
- 9.1.2 Procedure Volume Trends
- 9.1.3 Regulatory Environment
- 9.1.4 Competitive Landscape
- 9.1.5 Reimbursement Trends
9.2 Europe
- 9.2.1 Market Size & Forecast
- 9.2.2 Adoption of Drug-Coated Balloons
- 9.2.3 MDR Regulatory Impact
- 9.2.4 Competitive Landscape
- 9.2.5 Reimbursement Environment
9.3 Asia-Pacific
- 9.3.1 Market Size & Forecast
- 9.3.2 Expanding Interventional Cardiology Infrastructure
- 9.3.3 Regional Manufacturing Expansion
- 9.3.4 Regulatory Overview
- 9.3.5 Competitive Intensity
9.4 Latin America
- 9.4.1 Market Size & Forecast
- 9.4.2 Access to Interventional Procedures
- 9.4.3 Regulatory Environment
- 9.4.4 Competitive Landscape
9.5 Middle East & Africa
- 9.5.1 Market Size & Forecast
- 9.5.2 Healthcare Infrastructure Development
- 9.5.3 Regulatory Environment
- 9.5.4 Competitive Landscape

10. Key Countries Analysis

10.1 United States
- 10.1.1 Market Size & Forecast
- 10.1.2 PCI Procedure Volume
- 10.1.3 FDA Regulatory Framework
- 10.1.4 Reimbursement Landscape
- 10.1.5 Key Companies and Product Presence
10.2 Canada
- 10.2.1 Market Size & Forecast
- 10.2.2 Epidemiology and Procedure Trends
- 10.2.3 Regulatory Framework
- 10.2.4 Reimbursement Overview
- 10.2.5 Key Companies and Product Presence
10.3 Germany
- 10.3.1 Market Size & Forecast
- 10.3.2 PCI Volume Trends
- 10.3.3 MDR and National Regulatory Framework
- 10.3.4 Reimbursement Landscape
- 10.3.5 Key Companies and Product Presence
10.4 United Kingdom
- 10.4.1 Market Size & Forecast
- 10.4.2 Cardiovascular Disease Burden
- 10.4.3 MHRA Regulatory Environment
- 10.4.4 NHS Reimbursement Dynamics
- 10.4.5 Key Companies and Product Presence
10.5 France
- 10.5.1 Market Size & Forecast
- 10.5.2 Procedure Volume Trends
- 10.5.3 Regulatory Framework
- 10.5.4 Reimbursement Overview
- 10.5.5 Key Companies and Product Presence
10.6 Italy
- 10.6.1 Market Size & Forecast
- 10.6.2 Epidemiology Overview
- 10.6.3 Regulatory Environment
- 10.6.4 Reimbursement Landscape
- 10.6.5 Key Companies and Product Presence
10.7 Spain
- 10.7.1 Market Size & Forecast
- 10.7.2 PCI Adoption Trends
- 10.7.3 Regulatory Framework
- 10.7.4 Reimbursement Overview
- 10.7.5 Key Companies and Product Presence
10.8 China
- 10.8.1 Market Size & Forecast
- 10.8.2 Cardiovascular Disease Burden
- 10.8.3 NMPA Regulatory Framework
- 10.8.4 Volume-Based Procurement Impact
- 10.8.5 Key Companies and Product Presence
10.9 Japan
- 10.9.1 Market Size & Forecast
- 10.9.2 Aging Population Impact
- 10.9.3 PMDA Regulatory Framework
- 10.9.4 Reimbursement Landscape
- 10.9.5 Key Companies and Product Presence
10.10 India
- 10.10.1 Market Size & Forecast
- 10.10.2 Cardiovascular Disease Burden
- 10.10.3 CDSCO Regulatory Framework
- 10.10.4 Pricing and Reimbursement Dynamics
- 10.10.5 Key Companies and Product Presence
10.11 South Korea
- 10.11.1 Market Size & Forecast
- 10.11.2 Procedure Volume Trends
- 10.11.3 MFDS Regulatory Framework
- 10.11.4 Reimbursement Overview
- 10.11.5 Key Companies and Product Presence
10.12 Australia
- 10.12.1 Market Size & Forecast
- 10.12.2 Cardiovascular Disease Burden
- 10.12.3 TGA Regulatory Framework
- 10.12.4 Reimbursement Landscape
- 10.12.5 Key Companies and Product Presence
10.13 Brazil
- 10.13.1 Market Size & Forecast
- 10.13.2 Interventional Cardiology Trends
- 10.13.3 ANVISA Regulatory Framework
- 10.13.4 Reimbursement Environment
- 10.13.5 Key Companies and Product Presence
10.14 Mexico
- 10.14.1 Market Size & Forecast
- 10.14.2 Cardiovascular Disease Burden
- 10.14.3 COFEPRIS Regulatory Framework
- 10.14.4 Reimbursement Overview
- 10.14.5 Key Companies and Product Presence
10.15 Saudi Arabia
- 10.15.1 Market Size & Forecast
- 10.15.2 Cardiovascular Disease Trends
- 10.15.3 SFDA Regulatory Framework
- 10.15.4 Reimbursement Landscape
- 10.15.5 Key Companies and Product Presence
10.16 South Africa
- 10.16.1 Market Size & Forecast
- 10.16.2 Epidemiology Overview
- 10.16.3 SAHPRA Regulatory Framework
- 10.16.4 Reimbursement Environment
- 10.16.5 Key Companies and Product Presence

11. Regulatory & Policy Landscape

11.1 United States
- 11.1.1 FDA Device Classification
- 11.1.2 Premarket Approval (PMA) and 510(k) Pathways
- 11.1.3 UDI and Post-Market Surveillance
11.2 Europe
- 11.2.1 European MDR Framework
- 11.2.2 CE Marking Requirements
- 11.2.3 Clinical Evaluation Requirements
11.3 Japan
- 11.3.1 PMDA Approval Process
- 11.3.2 Reimbursement Listing Requirements
11.4 India
- 11.4.1 CDSCO Medical Device Regulations
- 11.4.2 Import and Manufacturing Compliance
11.5 China
- 11.5.1 NMPA Registration Requirements
- 11.5.2 Local Clinical Trial Requirements
11.6 Global Regulatory Harmonization
- 11.6.1 IMDRF Guidelines
- 11.6.2 ISO Standards for Balloon Catheters
- 11.6.3 Post-Market Vigilance Requirements

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Competitive Benchmarking
- 12.2.1 Product Portfolio Comparison
- 12.2.2 Technology Benchmarking
- 12.2.3 Geographic Presence
- 12.2.4 Strategic Collaborations
12.3 Recent Developments
- 12.3.1 Product Launches
- 12.3.2 FDA and CE Mark Approvals
- 12.3.3 Mergers and Acquisitions
- 12.3.4 Partnerships and Distribution Agreements
12.4 Competitive Positioning Matrix

13. Company Profiles

13.1 Abbott Laboratories
- 13.1.1 Company Overview
- 13.1.2 Balloon Angioplasty Portfolio

NC Trek RX Coronary Dilatation Catheter

Armada 35 PTA Balloon Catheter

Passeo-18 Lux Drug-Coated PTA Balloon Catheter

13.1.3 Key Indications
13.1.4 Pipeline and Innovation Focus
13.1.5 Financial Overview

13.2 Boston Scientific Corporation
- 13.2.1 Company Overview
- 13.2.2 Balloon Angioplasty Portfolio

Ranger Drug-Coated Balloon

Sterling Balloon Dilatation Catheter

Agent Drug-Coated Balloon

13.2.3 Key Indications
13.2.4 Pipeline and Clinical Programs
13.2.5 Financial Overview

13.3 Medtronic plc
- 13.3.1 Company Overview
- 13.3.2 Balloon Angioplasty Portfolio

Prevail Drug-Coated Balloon

Euphora Semi-Compliant Balloon Dilatation Catheter

Chocolate PTA Balloon Catheter

13.3.3 Key Indications
13.3.4 Pipeline and Innovation Focus
13.3.5 Financial Overview

13.4 Terumo Corporation
- 13.4.1 Company Overview
- 13.4.2 Balloon Angioplasty Portfolio

Ryurei PTCA Balloon Dilatation Catheter

Glider PTCA Balloon Catheter

Misago Peripheral Balloon Systems

13.4.3 Key Indications
13.4.4 Pipeline and Innovation Focus
13.4.5 Financial Overview

13.5 Becton, Dickinson and Company
- 13.5.1 Company Overview
- 13.5.2 Balloon Angioplasty Portfolio

Ultraverse PTA Balloon Dilatation Catheter

Lutonix Drug-Coated Balloon

Crosser CTO Recanalization System

13.5.3 Key Indications
13.5.4 Pipeline and Innovation Focus
13.5.5 Financial Overview

13.6 Koninklijke Philips N.V.
- 13.6.1 Company Overview
- 13.6.2 Balloon Angioplasty Portfolio

Stellarex Drug-Coated Balloon

Chocolate Touch Drug-Coated PTA Balloon

13.6.3 Key Indications
13.6.4 Pipeline and Innovation Focus
13.6.5 Financial Overview

13.7 BIOTRONIK SE & Co. KG
- 13.7.1 Company Overview
- 13.7.2 Balloon Angioplasty Portfolio

Pantera Lux Drug-Coated Balloon

Passeo-18 PTA Balloon Catheter

13.7.3 Key Indications
13.7.4 Pipeline and Clinical Programs
13.7.5 Financial Overview

13.8 B. Braun SE
- 13.8.1 Company Overview
- 13.8.2 Balloon Angioplasty Portfolio

SeQuent Please Drug-Coated Balloon

Passeo Balloon Catheter Family

13.8.3 Key Indications
13.8.4 Pipeline and Innovation Focus
13.8.5 Financial Overview

13.9 Cook Medical
- 13.9.1 Company Overview
- 13.9.2 Balloon Angioplasty Portfolio

Advance Enforcer 35 Focal Force PTA Balloon Catheter

Advance 18 LP Low Profile PTA Balloon Catheter

13.9.3 Key Indications
13.9.4 Pipeline and Innovation Focus
13.9.5 Financial Overview

13.10 Cardinal Health
- 13.10.1 Company Overview
- 13.10.2 Balloon Angioplasty Portfolio

Scoreflex NC Scoring PTCA Catheter

VascuTrak PTA Dilatation Catheter

13.10.3 Key Indications
13.10.4 Pipeline and Commercial Strategy
13.10.5 Financial Overview

14. Future Outlook

14.1 Future Market Trends
- 14.1.1 Shift Toward Drug-Coated Balloons
- 14.1.2 Growth in Peripheral Interventions
- 14.1.3 AI and Imaging Integration
- 14.1.4 Outpatient PCI Expansion
14.2 Emerging Technologies
- 14.2.1 Sirolimus-Coated Balloon Development
- 14.2.2 Next-Generation Specialty Balloons
- 14.2.3 Bioresorbable Technologies
14.3 Strategic Recommendations
- 14.3.1 Expansion Strategies for Emerging Markets
- 14.3.2 Product Differentiation Approaches
- 14.3.3 Regulatory and Reimbursement Strategy

15. Methodology

15.1 Research Methodology
- 15.1.1 Primary Research
- 15.1.2 Secondary Research
- 15.1.3 Data Triangulation
15.2 Market Estimation Model
- 15.2.1 Top-Down Approach
- 15.2.2 Bottom-Up Approach
15.3 Forecasting Assumptions
15.4 Abbreviations and Definitions
15.5 Sources and References